UMB Bank N A MO cut its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 12.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,354 shares of the medical instruments supplier’s stock after selling 895 shares during the period. UMB Bank N A MO’s holdings in C.R. Bard were worth $2,008,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of C.R. Bard by 1,365.7% in the first quarter. BlackRock Inc. now owns 7,398,081 shares of the medical instruments supplier’s stock valued at $1,838,719,000 after buying an additional 6,893,346 shares in the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in shares of C.R. Bard during the first quarter valued at approximately $132,062,000. Marshall Wace North America L.P. purchased a new stake in shares of C.R. Bard during the first quarter valued at approximately $132,062,000. Renaissance Technologies LLC increased its stake in shares of C.R. Bard by 87.8% in the first quarter. Renaissance Technologies LLC now owns 956,700 shares of the medical instruments supplier’s stock valued at $237,778,000 after buying an additional 447,300 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of C.R. Bard by 267.0% in the first quarter. Alliancebernstein L.P. now owns 491,184 shares of the medical instruments supplier’s stock valued at $122,079,000 after buying an additional 357,355 shares in the last quarter. Institutional investors own 85.32% of the company’s stock.
Shares of C.R. Bard, Inc. (NYSE BCR) opened at 319.75 on Friday. The company’s 50-day moving average is $319.00 and its 200-day moving average is $283.44. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $323.27. The stock has a market cap of $23.24 billion, a P/E ratio of 41.98 and a beta of 0.59.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.54 EPS. On average, equities research analysts anticipate that C.R. Bard, Inc. will post $11.84 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were paid a dividend of $0.26 per share. The ex-dividend date was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio (DPR) is presently 13.67%.
COPYRIGHT VIOLATION WARNING: “UMB Bank N A MO Has $2.01 Million Position in C.R. Bard, Inc. (NYSE:BCR)” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/08/12/umb-bank-n-a-mo-has-2-01-million-position-in-c-r-bard-inc-nysebcr.html.
BCR has been the subject of several analyst reports. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 target price for the company in a report on Thursday, May 11th. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 8th. Morgan Stanley downgraded shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. Jefferies Group LLC increased their target price on shares of C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a report on Monday, April 24th. Finally, Raymond James Financial, Inc. downgraded shares of C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a report on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $285.67.
In related news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the transaction, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.80% of the company’s stock.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.